Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Addition of a 5-HT receptor agonist to methylphenidate potentiates the reduction of [I-123]FP-CIT binding to dopamine transporters in rat frontal cortex and hippocampus
Autore:
Reneman, L; De Bruin, K; Lavalaye, J; Gunning, WB; Booij, J;
Indirizzi:
Acad Med Ctr, Dept Nucl Med, Grad Sch Neurosci, NL-1105 AZ Amsterdam, Netherlands Acad Med Ctr Amsterdam Netherlands NL-1105 AZ AZ Amsterdam, Netherlands Acad Med Ctr, Dept Child & Adolescent Psychiat, NL-1105 AZ Amsterdam, Netherlands Acad Med Ctr Amsterdam Netherlands NL-1105 AZ AZ Amsterdam, Netherlands
Titolo Testata:
SYNAPSE
fascicolo: 3, volume: 39, anno: 2001,
pagine: 193 - 200
SICI:
0887-4476(20010301)39:3<193:AOA5RA>2.0.ZU;2-W
Fonte:
ISI
Lingua:
ENG
Soggetto:
TYROSINE-HYDROXYLASE ACTIVITY; BRAIN-SEROTONIN NEURONS; IN-VIVO; TRYPTOPHAN-HYDROXYLASE; MONOAMINERGIC SYSTEMS; NUCLEUS-ACCUMBENS; MDMA ECSTASY; NEUROTOXICITY; METHAMPHETAMINE; METHYLENEDIOXYMETHAMPHETAMINE;
Keywords:
amphetamine analogs; methylphenidate; ADHD; neurotoxicity; 5-HT2 receptor agonists; dopamine transporters; SPECT;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
44
Recensione:
Indirizzi per estratti:
Indirizzo: Reneman, L Acad Med Ctr, Dept Nucl Med, Grad Sch Neurosci, Meibergdreef 9,F2N, NL-1105 AZ Amsterdam, Netherlands Acad Med Ctr Meibergdreef 9,F2N Amsterdam Netherlands NL-1105 AZ
Citazione:
L. Reneman et al., "Addition of a 5-HT receptor agonist to methylphenidate potentiates the reduction of [I-123]FP-CIT binding to dopamine transporters in rat frontal cortex and hippocampus", SYNAPSE, 39(3), 2001, pp. 193-200

Abstract

The neurotoxic potential of amphetamine and related drugs is well documented. However, methylphenidate, an amphetamine derivative used in the treatment of attention deficit hyperactivity disorder, and known to increase synaptic dopamine (DA) levels, seems to lack neurotoxic potential. It is hypothesized that both dopaminergic and serotonergic systems are involved in the neurotoxicity of amphetamine derivatives. The purpose of the present study was to evaluate the neurotoxic potential of methylphenidate and to test whether stimulation of the serotonergic system may confer neurotoxic propertiesto methylphenidate for DA or serotonin (5-HT) neurons. In addition, the present study was undertaken to evaluate the necessity to perform future SPECT studies in individuals using both methylphenidate and Ei-HT-acting agents. We therefore measured monoaminergic transporters in rat brain using radioligands suitable for SPECT imaging ([I-123]beta -CIT and [I-123]FP-CIT). Groups of rats were treated with methylphenidate or saline for 4 days. Additional groups were treated with the selective 5-HT2 receptor agonist quipazine or the selective 5-HT reuptake blocker fluoxetine, alone or in combination with methylphenidate. Binding studies were performed 5 days after the last treatment. In a second experiment, methylphenidate in combination with quipazine, along with a control group, was retested. In this experiment, monoaminergic terminal density was estimated 2 weeks (rather than 5 days) afterdrug treatment. Five days, but not 2 weeks, after treatment a significant reduction in specific [I-123]FP-CIT binding was observed in the frontal cortex and hippocampus of rats treated with methylphenidate in combination with quipazine. These changes probably do not reflect neurotoxic changes of frontal cortex and hippocampal DA terminal markers, but a compensatory downregulation of DA transporters. These findings suggest potential harmful effects of concomitant use of drugs directly activating 5-HT2 receptors in patients using methylphenidate. (C) 2001 Wiley-Liss, Inc.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 19/01/20 alle ore 06:51:40